OncoMatch/Clinical Trials/NCT07085559
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Is NCT07085559 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Metabolically Armed BCMA CAR-T cells. for multiple myeloma (mm).
Treatment: Metabolically Armed BCMA CAR-T cells. — A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) cell membrane BCMA expression
Evidence of cell membrane BCMA expression, as determined by a validated immunohistochemistry (IHC) or flow cytometry of tumor tissue.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
at least 3 prior lines of therapy (including chemotherapy based on proteasome inhibitors and immunomodulatory agents)
Must have received: immunomodulatory agent
at least 3 prior lines of therapy (including chemotherapy based on proteasome inhibitors and immunomodulatory agents)
Cannot have received: hematopoietic stem cell transplant
Exception: HSCT within 2 months prior to the start of infusion of Meta10-BCMA
Any hematopoietic stem cell transplant(HSCT) within 2 months prior to the start of infusion of Meta10-BCMA
Lab requirements
Blood counts
ANC ≥1×10^9 /L; hemoglobin ≥70 g/L; platelets ≥50×10^9 /L; ALC ≥0.3×10^9 /L
Kidney function
Serum creatinine ≤2.5×ULN, or CrCl ≥ 60 ml/min
Liver function
ALT and AST ≤ 2.5×ULN; total serum bilirubin ≤ 1.5×ULN
Cardiac function
LVEF ≥ 50%
Subjects should have adequate organ function: ... CBC ... ALT and AST ≤ 2.5×ULN; total serum bilirubin ≤ 1.5×ULN ... Serum creatinine ≤2.5×ULN, or CrCl ≥ 60 ml/min ... LVEF ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07085559 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior hematopoietic stem cell transplant disqualifies patients from enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 cell membrane BCMA expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages